| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1038804762 |
| P356 | DOI | 10.1007/S00702-008-0174-9 |
| P932 | PMC publication ID | 2953764 |
| P698 | PubMed publication ID | 19156349 |
| P5875 | ResearchGate publication ID | 23804182 |
| P50 | author | Kjell Fuxe | Q5747854 |
| Luca Ferraro | Q38548471 | ||
| Sergio Tanganelli | Q40454146 | ||
| Tiziana Antonelli | Q42804912 | ||
| Daniel Marcellino | Q55608902 | ||
| Luigi Francesco Agnati | Q67459743 | ||
| A.S. Woods | Q67459759 | ||
| P2093 | author name string | Leo Giuseppina | |
| P2860 | cites work | Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. | Q24305024 |
| Dopamine D2 receptors form higher order oligomers at physiological expression levels | Q24318766 | ||
| Detection of higher-order G protein-coupled receptor oligomers by a combined BRET-BiFC technique | Q24319792 | ||
| Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes | Q24563287 | ||
| Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization | Q24653438 | ||
| Identification of a serotonin/glutamate receptor complex implicated in psychosis | Q24655484 | ||
| Serotonin model of schizophrenia: emerging role of glutamate mechanisms | Q28138722 | ||
| Gating of information flow within the limbic system and the pathophysiology of schizophrenia | Q28138727 | ||
| Oligomerization of adenosine A2A and dopamine D2 receptors in living cells | Q28178824 | ||
| EVIDENCE FOR THE EXISTENCE OF MONOAMINE-CONTAINING NEURONS IN THE CENTRAL NERVOUS SYSTEM. I. DEMONSTRATION OF MONOAMINES IN THE CELL BODIES OF BRAIN STEM NEURONS | Q28201187 | ||
| Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors | Q28204434 | ||
| Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial | Q28244389 | ||
| Dopamine D3 receptor antagonists as therapeutic agents | Q28259541 | ||
| Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function | Q28261240 | ||
| Neurotensin receptors as modulators of glutamatergic transmission | Q28261782 | ||
| Cocaine seeking habits depend upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum | Q28267577 | ||
| Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis | Q28268078 | ||
| Allosteric modulation of dopamine D2 receptors by homocysteine | Q28271922 | ||
| Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons | Q28272251 | ||
| Metabotropic glutamate receptors in the basal ganglia motor circuit | Q28280931 | ||
| Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior | Q28286238 | ||
| Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes | Q28292838 | ||
| Modulation of D2R-NR2B interactions in response to cocaine | Q28566108 | ||
| Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids | Q28571785 | ||
| The molecular logic of endocannabinoid signalling | Q29615356 | ||
| Getting formal with dopamine and reward | Q29618725 | ||
| D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons | Q29619181 | ||
| Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction | Q30053550 | ||
| Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system | Q30472844 | ||
| Dichotomous dopaminergic control of striatal synaptic plasticity | Q30493521 | ||
| Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens | Q30499463 | ||
| Volumes of association thalamic nuclei in schizophrenia: a postmortem study | Q30769853 | ||
| The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorders | Q30888331 | ||
| Pathology of the thalamus and schizophrenia--an overview | Q30975598 | ||
| S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. | Q31399596 | ||
| Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? | Q33211909 | ||
| D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics | Q33692872 | ||
| Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug | Q33995048 | ||
| Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis | Q34200326 | ||
| Neurotensin: dual roles in psychostimulant and antipsychotic drug responses | Q34205082 | ||
| Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling | Q34330621 | ||
| Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs | Q34338202 | ||
| A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models | Q34377770 | ||
| CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder | Q34431402 | ||
| Heterodimerization of G-protein-coupled receptors in the CNS. | Q34442026 | ||
| Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action | Q34485906 | ||
| Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum | Q34507515 | ||
| Psychosis pathways converge via D2high dopamine receptors | Q34540180 | ||
| Cooperativity and biological complexity | Q37222211 | ||
| Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs | Q37332784 | ||
| Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions | Q37800377 | ||
| The current status of the dopamine hypothesis of schizophrenia | Q39577491 | ||
| From motivation to action: functional interface between the limbic system and the motor system. | Q40291930 | ||
| Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors | Q40516448 | ||
| Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex | Q40629393 | ||
| Expression of dopamine D3 receptor dimers and tetramers in brain and in transfected cells | Q41079818 | ||
| The nucleus accumbens: gateway for limbic structures to reach the motor system? | Q41091607 | ||
| Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic acid diethylamide | Q41355565 | ||
| Dopamine activation of endogenous cannabinoid signaling in dorsal striatum | Q41646203 | ||
| Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons | Q42466412 | ||
| Subchronic haloperidol increases CB(1) receptor binding and G protein coupling in discrete regions of the basal ganglia | Q42484267 | ||
| Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens | Q42492206 | ||
| Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 | ||
| Serotonergic basis of antipsychotic drug effects in schizophrenia. | Q42537934 | ||
| The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease | Q42546097 | ||
| Discovering risperidone: the LSD model of psychopathology | Q43068768 | ||
| Presynaptic adenosine A2A receptors enhance GABAergic synaptic transmission via a cyclic AMP dependent mechanism in the rat globus pallidus | Q43263782 | ||
| Biochemical characterization of the intramembrane interaction between neurotensin and dopamine D2 receptors in the rat brain | Q43468028 | ||
| D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. | Q43513203 | ||
| D2/D3 dopamine receptor heterodimers exhibit unique functional properties | Q43617477 | ||
| Relationships of 5-hydroxytryptamine immunoreactive terminal-like varicosities to 5-hydroxytryptamine-2A receptor-immunoreactive neuronal processes in the rat forebrain | Q43719699 | ||
| The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors | Q43737554 | ||
| Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. | Q43978573 | ||
| Neurotensin-induced modulation of dopamine D2 receptors and their function in rat striatum: counteraction by a NTR1-like receptor antagonist. | Q43984667 | ||
| The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys | Q44246256 | ||
| Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents | Q44378869 | ||
| Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer | Q44559398 | ||
| Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole | Q44612074 | ||
| Metabotropic glutamate 2/3 receptors as drug targets | Q44798168 | ||
| A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic Transmission | Q44853701 | ||
| Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. | Q45935762 | ||
| Do dopamine partial agonists have partial efficacy as antipsychotics? | Q46141097 | ||
| The genetics of schizophrenia converge upon the NMDA glutamate receptor. | Q46149556 | ||
| Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist | Q46510974 | ||
| Cooperativity in macromolecular assembly | Q46725345 | ||
| Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors | Q46841675 | ||
| Cannabidiol monotherapy for treatment-resistant schizophrenia | Q46886103 | ||
| CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates | Q48153202 | ||
| Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. | Q48217036 | ||
| Strongly reduced number of parvalbumin-immunoreactive projection neurons in the mammillary bodies in schizophrenia: further evidence for limbic neuropathology | Q48219154 | ||
| Adenosine A2A and group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D2 receptors in the rat striatum | Q48244540 | ||
| Role of the endogenous cannabinoid system in the regulation of motor activity | Q48285177 | ||
| Dopaminergic innervation of the rat prefrontal cortex: A fluorescence histochemical study | Q48392552 | ||
| Role of monoamines in the control by hormones of sexual receptivity in the female rat. | Q48446541 | ||
| Stimulation of D2 receptors in the prefrontal cortex reduces PCP-induced hyperactivity, acetylcholine release and dopamine metabolism in the nucleus accumbens | Q48451535 | ||
| Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A) receptor antagonists | Q48483341 | ||
| Hallucinogenic phenylethylamines: interactions with serotonin turnover and receptors | Q48583846 | ||
| Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. | Q48658239 | ||
| l-Glutamate reduces the affinity of [3H]N-propylnorapomorphine binding sites in striatal membranes | Q48683197 | ||
| Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing | Q48684396 | ||
| Volume and neuron number of the mediodorsal thalamic nucleus in schizophrenia: a replication study | Q48691206 | ||
| Neurotensin in vitro markedly reduces the affinity in subcortical limbic 3H-N-propylnorapomorphine binding sites | Q48711532 | ||
| Effects of 5-methoxy-N,N-dimethyltryptamine on central monoamine neurons | Q48748951 | ||
| Quantitative receptor autoradiography: application to the study of multiple serotonin receptors in rat cortex. | Q48824282 | ||
| Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics | Q48865852 | ||
| Coordinated expression of dopamine receptors in neostriatal medium spiny neurons | Q48890601 | ||
| Increase in spontaneous motor activity following infusion of neurotensin into the ventral tegmental area | Q49130429 | ||
| Lysergic Acid Diethylamide: Sensitive Neuronal Units in the Midbrain Raphe | Q49157889 | ||
| Neurotensin counteracts apomorphine-induced inhibition of dopamine release as studied by microdialysis in rat neostriatum. | Q51746020 | ||
| Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation. | Q51797175 | ||
| Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. | Q51902545 | ||
| Stereological analysis of the mediodorsal thalamic nucleus in schizophrenia: volume, neuron number, and cell types. | Q52000103 | ||
| The CB(1) cannabinoid receptor juxtamembrane C-terminal peptide confers activation to specific G proteins in brain. | Q52537508 | ||
| Regulation of DARPP-32 phosphorylation by Δ9-tetrahydrocannabinol | Q56504097 | ||
| Coordinated Expression of Dopamine Receptors in Neostriatal Medium Spiny Neurons | Q56568482 | ||
| Basal forebrain in the context of schizophrenia | Q56883821 | ||
| Adenosine A2A Agonists: A Potential New Type of Atypical Antipsychotic | Q60050265 | ||
| Chronic imipramine treatment reduces (+)2-[125I]iodolysergic acid, diethylamide but not 125I-neuropeptide Y binding in layer IV of rat cerebral cortex | Q60050293 | ||
| Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia | Q60644883 | ||
| Striatonigrostriatal Pathways in Primates Form an Ascending Spiral from the Shell to the Dorsolateral Striatum | Q64356882 | ||
| Hallucinogenic drugs of the indolealkylamine type and central monoamine neurons | Q70637070 | ||
| Strong effects of NT/NN peptides on DA D2 receptors in rat neostriatal sections | Q72404320 | ||
| Neurotensin: perchance an endogenous neuroleptic? | Q72431662 | ||
| Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia | Q72649876 | ||
| Organization of the output of the ventral striatopallidal system in the rat: ventral pallidal efferents | Q72697905 | ||
| Dopamine D3 receptors expressed by all mesencephalic dopamine neurons | Q73258546 | ||
| Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions | Q73553177 | ||
| Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs | Q73553193 | ||
| EVIDENCE FOR THE EXISTENCE OF MONOAMINE NEURONS IN THE CENTRAL NERVOUS SYSTEM. IV. DISTRIBUTION OF MONOAMINE NERVE TERMINALS IN THE CENTRAL NERVOUS SYSTEM | Q78461908 | ||
| EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. | Q34540614 | ||
| Targeting adenosine A2A receptors in Parkinson's disease | Q34571644 | ||
| From the Golgi-Cajal mapping to the transmitter-based characterization of the neuronal networks leading to two modes of brain communication: wiring and volume transmission | Q34619017 | ||
| A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis | Q34631718 | ||
| Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. | Q34638023 | ||
| Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology | Q34742184 | ||
| Detection of heteromerization of more than two proteins by sequential BRET-FRET. | Q34790164 | ||
| A postmortem study of the mediodorsal nucleus of the thalamus in schizophrenia. | Q35068136 | ||
| Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. | Q35180310 | ||
| Subnucleus-specific loss of neurons in medial thalamus of schizophrenics | Q35203213 | ||
| Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease | Q35603265 | ||
| Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders | Q35804715 | ||
| Understanding noncovalent interactions: ligand binding energy and catalytic efficiency from ligand-induced reductions in motion within receptors and enzymes | Q35981484 | ||
| Neurotransmitter receptor heteromers and their integrative role in 'local modules': the striatal spine module. | Q36087867 | ||
| The impact of G-protein-coupled receptor hetero-oligomerization on function and pharmacology | Q36162453 | ||
| Cannabinoid receptor homo- and heterodimerization | Q36174902 | ||
| Is the GABA B heterodimer a good drug target? | Q36191594 | ||
| Retrograde endocannabinoid signaling at striatal synapses requires a regulated postsynaptic release step | Q36300113 | ||
| The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders | Q36448714 | ||
| Prominence of the dopamine D2 short isoform in dopaminergic pathways | Q36507451 | ||
| Neurotensin: role in psychiatric and neurological diseases. | Q36557460 | ||
| A boolean network modelling of receptor mosaics relevance of topology and cooperativity | Q36586576 | ||
| Intramembrane receptor-receptor interactions: a novel principle in molecular medicine. | Q36635157 | ||
| Mesolimbic dopamine and cortico-accumbens glutamate afferents as major targets for the regulation of the ventral striato-pallidal GABA pathways by neurotensin peptides | Q36797523 | ||
| Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease | Q36873486 | ||
| Neurotensin receptor mechanisms and its modulation of glutamate transmission in the brain: relevance for neurodegenerative diseases and their treatment. | Q36900640 | ||
| Behavioural and physiological effects of electrical stimulation in the nucleus accumbens: a review. | Q36906892 | ||
| Role of cooperativity in protein folding and protein mosaic assemblage relevance for protein conformational diseases. | Q36990409 | ||
| Structural plasticity in G-protein coupled receptors as demonstrated by the allosteric actions of homocysteine and computer-assisted analysis of disordered domains. | Q37005557 | ||
| Allosteric modulation of heterodimeric G-protein-coupled receptors. | Q37005570 | ||
| The ventral striatum as an interface between the limbic and motor systems | Q37046585 | ||
| Evidence for a substrate of neuronal plasticity based on pre- and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum | Q37067348 | ||
| Adaptive properties and heterogeneity of dopamine D(2) receptors - pharmacological implications | Q37176758 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | brain | Q1073 |
| G protein-coupled receptor | Q38173 | ||
| schizophrenia | Q41112 | ||
| P304 | page(s) | 923-39 | |
| P577 | publication date | 2009-08-01 | |
| P1433 | published in | Journal of Neural Transmission | Q15750921 |
| P1476 | title | Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophrenia | |
| P478 | volume | 116 |
| Q37719729 | Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders. |
| Q43044221 | An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A(2A), dopamine D(2), cannabinoid CB(1), and metabotropic glutamate mGlu(5) receptors |
| Q38012473 | Aspects on the integrative actions of the brain from neural networks to "brain-body medicine". |
| Q36990269 | Characterisation of cannabinoid 1 receptor expression in the perikarya, and peripheral and spinal processes of primary sensory neurons |
| Q36402504 | Common variants in DRD2 are associated with sleep duration: the CARe consortium |
| Q42186802 | Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics |
| Q49024094 | Design, synthesis and biological evaluation of novel bivalent ligands targeting Dopamine D2-like receptors and µ opioid receptor |
| Q38214620 | Diversity and Bias through Receptor-Receptor Interactions in GPCR Heteroreceptor Complexes. Focus on Examples from Dopamine D2 Receptor Heteromerization. |
| Q38794247 | Dopamine D2 and serotonin 5-HT1A receptor interaction in the context of the effects of antipsychotics - in vitro studies |
| Q42050477 | Extrasynaptic neurotransmission in the modulation of brain function. Focus on the striatal neuronal-glial networks. |
| Q37739478 | On the expanding terminology in the GPCR field: the meaning of receptor mosaics and receptor heteromers. |
| Q38535579 | On the role of the extracellular space on the holistic behavior of the brain |
| Q35867186 | RGS4 overexpression in the rat dorsal striatum modulates mGluR5- and amphetamine-mediated behavior and signaling |
| Q38595178 | Role of iso-receptors in receptor-receptor interactions with a focus on dopamine iso-receptor complexes. |
| Q39418365 | Selective agonists for dopamine/neurotensin receptor heterodimers |
| Q24564171 | The G protein-coupled receptor heterodimer network (GPCR-HetNet) and its hub components |
| Q50090334 | The brain as a "hyper-network": the key role of neural networks as main producers of the integrated brain actions especially via the "broadcasted" neuroconnectomics. |
| Q37777734 | The changing world of G protein-coupled receptors: from monomers to dimers and receptor mosaics with allosteric receptor-receptor interactions |
| Q28087558 | The role of transmitter diffusion and flow versus extracellular vesicles in volume transmission in the brain neural-glial networks |
| Q34171499 | Theoretical considerations on the topological organization of receptor mosaics |
Search more.